Key facts
- Signify Bio’s last known valuation is $41.0M (Jun 2025).
- It has raised $15.0M; the latest was Early Stage VC ($15.0M) in Jun 2025.
- Notable investors include Gates Foundation, ACS BrightEdge, Actium (Dallas), Danaher, Eli Lilly.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Signify Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Signify Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Signify Bio
Operator of a biotechnology platform designed to transform the development of in situ protein therapeutics. The company offers signal peptide engineered control combined with mRNA encoded design, enabling patients with various diseases targeted and localized delivery of therapeutic proteins.
- Sector
- Healthcare
- HQ
- Dallas, TX, United States
- Founded
- 2024
- Website
- signifybio.com/
- Ownership
- Privately Held (backing)
Signify Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Signify Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Signify Bio in its N-PORT filings yet. We sweep new filings monthly.